US Dollar vs Yen

登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

ホーム
投資
株式
アメリカ
NASDAQ
Mineralys Therapeutics Inc (MLYS)
Mineralys Therapeutics Inc (MLYS) ニュース

Mineralys Therapeutics Inc (MLYS)

27.69

0.80

(2.98%)

終了 7月6日 5:00AM

27.69

0.01

(0.04%)

取引時間後: 8:59AM

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic...

Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

RADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a...

Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)

RADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

RADNOR, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a...

Form 8-K - Current report

Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing

– Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to...

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful...

Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference

RADNOR, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a...

Form 8-K - Current report

Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

– Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontrolled...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

– NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of December 22...

William777

William777 17分前

AI Summary
Nutranomics Inc. has ceased operations due to financial difficulties.
The company faced challenges in maintaining profitability and market competition.
Key products and services may no longer be available to consumers.
Employees were informed of layoffs and the

boston745

boston745 21分前

As far as finding you saying that specific quote, I will not find it. Thats something mainly found with Atlanta and I believe Madg. The part that says essentially derisk is me paraphrasing.

you guys warned me that Mgmt intended to use the public markets to essentially derisk the IP an

jondoeuk

jondoeuk 23分前

You're responding to an argument I didn't make. My comments were about the trial's methodology, endpoints, and more. If you disagree, you can start by explaining why the negative prespecified primary endpoint and the lack of a published randomised OS analysis don't matter, rather than telling me wha

jxyzobrien

jxyzobrien 26分前

dalton this week

https://www.youtube.com/watch?v=5QLj9AvceJ8

TheVale-ai

TheVale-ai 30分前

Gents, Now that APPLE is heavily invested in Credit Cards and Affinity Marketing, I wonder if they might one day enter the Fractional Shares space, taking on HOOD. It would be an Ace, my fund thinks. That is, a MONEY stock.

getmoreshares

getmoreshares 34分前

It was stated in one of the interviews "it works"

Vexari

Vexari 35分前

Points

www.msn.com/en-us/sports/moto_gp/how-one-single-nascar-cup-series-point-just-turned-into-50/ar-AA27fHDy?ocid=msedgntp&pc=W069&cvid=6a4a69669b1b4bdd935811a9192faa1b&ei=19 And the battle for the regular season championship

StarryComet61

StarryComet61 37分前

There was an r/s to bring the price to Nasdaq though. It went to like 3.00 and then it went all the way down to .30, and then there was an r/s to bring it back to 3. Then a year later it ran to 75 or whatever it was.

Renorocker

Renorocker 37分前

Even at a 8/1 ratio, that brings the OS under 1B.
.25 puts me on an endless beach under the stars, actually .10 does that too.

sage007

sage007 40分前

You sound increasingly like a paid pumper. Why are you twisting what was written? You keep editing and changing and shifting like scums that are posting here as employees of MMs. Are you being paid by NWBio to pump and keep retail investors hooked? I clearly said that the presentation is a non-ev

learningcurve2020

learningcurve2020 42分前

If you really believe all BP is against this company then your investment is doomed. But it might explain why management never ever made any open market purchases? 🤔🤷‍♀️

Vexari

Vexari 43分前

againstallodds

againstallodds 43分前

Now July 7th, still no disclosed Lumb transactions

Hey Stephen, was you plot debunked before you even had a chance to disclose the details ?

We’re still waiting for your new hyped-up pipe dream…

https://investorshub.advfn.com/uimage/uploads/2020/11/22/vtz

wallstreet1231

wallstreet1231 44分前

Will an 8k filing be forthcoming?

learningcurve2020

learningcurve2020 46分前

He does very well on STAT which is where the true pros reside.

RRP60

Opinions can be on both sides of the line. Its healthy and i respect it. Here in our case its biased. The shorts voicing here get BP or their HF sponsorship as they will benefit if our technology dies in its tracks. Whereas the longs are supporting this company due to their conviction in its scienc

Zadie420

Zadie420 47分前

Don't forget to include Dr. P Kalinski work to ongoing HER2/HER3 breast cancer trial and P2 Ovarian cancer starting next month (August).
I think Dr. P Kalinski work will be focused on Women's cancer type.

STL Stock

STL Stock 51分前

Dollar volume? About 12 million or more would be my guess.

DrHigh

DrHigh 51分前

Special place in hell for shills like him

learningcurve2020

learningcurve2020 53分前

…but truly the real questions are Why Powers never shows herself? Why no CFO and the lousy funding? Why such a poorly maintained website? Why never any open market purchases? Why no more trials? Why no pediatric trial? Why no Specials revenue? Why didn’t she ever extend an olive branch to Adam inste

bobby1151

bobby1151 55分前

WRONG answer "WHELANer" try 2 B nice!!!!!

iHub Time Traveler

iHub Time Traveler 57分前

Short interest (short selling positions) in SpaceX (NASDAQ: SPCX) recently reached approximately 31% of the free float (shares available for trading).

When the unlocking begins, there will be blood in the streets.

Sammy boy

Sammy boy 58分前

Ever since Bessent cold cocked Tommy Boy the stock has bleed. 4 months ago, I said Bessent is the problem !

elks

Same here loading more breakout here soon. Big days and weeks ahead. Tic. Toc. Good luck to everyone. Lfg.

Mineralys Therapeutics

0.7600% until 25.05.2066...

AXS 2X PFE Bull Daily ETF

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。